Overcoming critical challenges in AI-driven drug discovery
Supported by:
25 November 2024
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer insights into how they can be overcome.
Join us for this webinar as we investigate how challenges in AI-driven drug discovery can be overcome. In this webinar, esteemed experts will explore strategies to improve data collection, integration and curation, the importance of model interpretability and the latest advancements in explainable AI.
Also, our panellists will discuss how scientists can collaborate with regulators to create frameworks that both support innovation and ensure ethical research practices. Furthermore, success stories in bridging the gap between traditional drug discovery methods and AI-driven approaches will be shared.
Key learning points:
- Ensuring data quality and diversity: Our panellists will discuss strategies for improving data collection, integration and curation to ensure AI models are trained on high-quality, unbiased and diverse datasets. They will also explain approaches to managing data scarcity in rare diseases, and how to overcome biases in existing datasets.
- Importance of model interpretability: The latest advancements in explainable AI (XAI) will be elucidated, as well as how these advancements can build trust with regulators, researchers and industry stakeholders.
- Generalisation and transferability of AI models: The challenges of generalising AI models from preclinical animal studies to human applications will be explained, as well as the methodologies for improving the transferability of AI insights.
- Navigating ethical, legal and regulatory landscapes: Our panellists will explore the ethical considerations, data privacy issues and intellectual property challenges associated with AI, and how scientists can work with regulators to create frameworks that both support innovation and ensure ethical research practices.
- Building trust in AI solutions: Despite some scepticism surrounding the adoption of AI, success stories that have bridged the gap between traditional drug discovery methods and AI-driven approaches will be shared.
Register now to secure your place!
Claudia Zylberberg, Kosten Digital Angela Lai, CEO and Founder of Betteromics Dalip Sethi, Terumo Blood and Cell Technologies He holds a doctorate and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. In his post-doctoral research, Dalip focused on the development of cancer gene-specific RNA and DNA analogs targeted against cancer genes in the signal transduction pathway for use as cancer diagnostics and therapeutics. Throughout his career in the industry, Dalip has been engaged in developing technologies and methods for use in cell therapy applications. Dalip has authored multiple scientific publications and is a co-inventor on several patents and patent applications. He recently co-authored publications on modular automated systems for CD3+ T-cell manufacturing and monoculture of cord-blood derived CD34+ using an automated, membrane-based dynamic perfusion system. The articles highlighted the benefits of modular automation in cell therapy manufacturing. Dalip is also an ISCT member and participates in committees focused on cold chain, particulates, and process analytical technologies. Edward Kliphuis, Partner, Sofinnova Partners – Digital Medicine Strategy Before that, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap life sciences equities. He started his career as an analyst within the biopharma investment team of M Ventures. Edward is positive, energetic and purpose-driven — and he enjoys a challenge. In 2012, for instance, he took on the Gobi Desert in an underpowered 1.2L Chevrolet Aveo, which he and his team drove from London to Mongolia to raise money for SOS Children’s Villages. He holds an MSc in Biopharmaceutical Sciences from Leiden University, The Netherlands, with a specialisation in pharmacology. Yochi Slonim MSc, Co-Founder & CEO, Board Member of Anima Biotech Prior to Anima, Yochi was a co-founder of Mercury Interactive. As CTO and VP R&D from the company’s early days, he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B. As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m. In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in less than 5 years and was acquired by BMC in 2006 for $150m in cash. Yochi founded ffwd.me, a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors. As one of Israel’s leading speakers on the subject of startup positioning and company building, several of Yochi’s approachable and amusing lectures can be found on Youtube (“Youtube Yochi Slonim”). Is the webinar free? When will the webinar take place? I’m busy. Can I watch it later? What are the benefits of attending live? How long will the webinar be? What do I need to watch this webinar? Do I receive a certificate?OUR SPEAKERS
Claudia Zylberberg, PhD, is the Founder and former CEO of Akron Bio, and a current Board member. She has more than 25 years’ experience in the biomedical research and biotechnology industries and first-hand knowledge of what it takes to bring products through R&D and on to approval and commercialization. She is highly knowledgeable about current FDA regulations, qualifications of raw materials, process design and validation, and bioassay development. Dr. Zylberberg also has expertise in recombinant proteins, media development, combinational (devices), and platform technologies. She is the inventor of numerous patented proprietary technologies and has an extensive peer-reviewed publication record. Dr Zylberberg is proud to be an advisor and consultant to organizations worldwide regarding the regulatory roadmap and commercialization of cell therapies and stem cell banking. She was part of the strategic advisory council of the International Society for Cell and Gene Therapy (ISCT) and holds many non-executive positions: Co-founder and Board Member of the Standard Coordinating Body for Regenerative Medicine; Board Member of Canadian Consortia for Regenerative Medicine; Chair of the Board, ARScience Biotherapeutics; Scientific Board Member and Advisor, Advisor @ Phacilitate; Co-founder and Board Member, Kosten Digital; Board Member, BDB Palm Beach Life Sciences; and was a Mentor, Creative Destruction Lab. Previous roles include the following: Board Member, BioFlorida; former Treasurer and Executive Board Member of the Alliance for Regenerative Medicine (ARM); Chair of the Industry Advisory Board, West Palm Beach, Florida, among others. Children’s book writer “You’re Full of Genes”
As an innovative and transformational scientific leader, Dalip Sethi, PhD, currently serves as the scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio.
Edward is a Partner in the Sofinnova Digital Medicine Strategy. He joined in 2021 from M Ventures, Merck KGaA’s corporate VC arm, where he focused on investments in cutting-edge digital medicine companies, including developers of the first FDA-approved videogame therapy.
A serial entrepreneur in software and biotech, Yochi Slonim has built multiple companies as a founder and CEO through all phases of growth all the way to IPOs and large M&A exits. As a Co-founder and CEO of Anima Biotech, he is driving the company’s strategy and business development at the intersection of mRNA biology and AI.FAQs
Yes – there is no charge to watch the webinar, either live or on-demand.
The webinar will take place live on 25 November 2024 at 3PM GMT.
The webinar will become available to watch on-demand shortly after the live webinar takes place.
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
This webinar will last for up to one hour.
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.